Please use this identifier to cite or link to this item: http://lib.jncasr.ac.in:8080/jspui/handle/10572/574
Title: PBEF1/NAmPRTase/Visfatin - A potential malignant astrocytoma/glioblastoma serum marker with prognostic value
Authors: Reddy, P Sreekanth
Umesh, Srikantha
Thota, Balaram
Tandon, Ashwani
Pandey, Paritosh
Hegde, A S
Balasubramaniam, Anandh
Chandramouli, B A
Santosh, Vani
Rao, M R S
Kondaiah, Paturu
Somasundaram, Kumaravel
Keywords: glioma
astrocytoma
glioblastoma multiforme
microarray
PBEF1
serum marker
survival analysis
nampt
visfatin
prognosis
Colony-Enhancing Factor
Nicotinamide Phosphoribosyltransferase
Glioblastoma
Survival
Therapy
Cancer
Expression
Apoptosis
Profile
Genes
Issue Date: May-2008
Publisher: Landes Bioscience
Citation: Cancer Biology & Therapy 7(5), 663-668 (2008)
Abstract: Malignant astrocytomas comprise anaplastic astrocytoma (AA; grade III) and Glioblastoma (GBM; grade IV). GBM is the most malignant with a median survival of 10-12 months in patients. Using cDNA microarray based expression profiling of different grades of astrocytomas, we identified several fold increased levels of PBEF1 transcripts in GBM samples. Pre-B-cell colony enhancing factor 1 gene (PBEF1) encodes Nicotinamide phosphoribosyltransferase (NAmPRTase), which catalyses the rate limiting step in the salvage pathway of NAD metabolism in mammalian cells. Further validation using real time RT-qPCR on an independent set of tumor samples (n = 91) and normal brain samples (n = 9), GBM specific higher expression of PBEF1 was confirmed. Immunohistochemical staining for PBEF1 on a subset of the above samples largely reinforced our finding. We carried out ELISA analysis on serum samples of astrocytoma patients to determine whether this protein levels would correlate with the presence of tumor and tumor grade. PBEF1 serum levels were substantially elevated in many of the AA and GBM patients. Statistical analysis of these data indicates that in patients with astrocytoma, serum PBEF1 levels correlate with tumor grade and is highest in GBM. Immunohistochemical analysis of an independent set of 51 retrospective GBM cases with known survival data revealed that PBEF1 expression in the tumor tissue along with its co-expression with p53 was associated with poor survival. Thus, we have identified PBEF1 as a potential malignant astrocytoma serum marker and prognostic indicator among GBMs.
Description: Restricted Access
URI: http://hdl.handle.net/10572/574
Other Identifiers: 1538-4047
Appears in Collections:Research Papers (M.R.S. Rao)

Files in This Item:
File Description SizeFormat 
sl.no.121.2008 Cancer Biology & Therapy 7, 665-670 May.pdf
  Restricted Access
778.8 kBAdobe PDFView/Open Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.